This event is now fully booked.
Join us for the official launch of Innovation Week 2018 – A celebration of STEMM innovation and entrepreneurship.
Starting with the inaugural Innovation Week in 2015, this initiative is now in its fourth year and is an annual celebration of innovation in science, technology, engineering, mathematics and medicine (STEMM) in Australia led by the Australian Science and Innovation Forum (ASIF) in partnership with the Australian Academy of Technological Sciences and Engineering (ATSE).
The goal of the week is to foster an innovation culture that values basic research, features the translation of discoveries, celebrates successful teams as well as emerging entrepreneurs and start-ups.
The theme for this year’s Innovation Week launch is “Making Industry Partnerships Work”.
The rise of a global knowledge economy has encouraged the need for strategic partnerships between industry and university that go beyond discrete academic only research projects. When done well, strategic partnerships combine the discovery-driven culture of the university with the innovation-driven environment of the company to help drive economic growth and tackle key social challenges. We will hear from university and industry leaders who are at the helm of such partnerships and can speak to what structures make for excellent partnerships and what approach produces seamless industry & university partnerships.
Date: Monday, 12 November 2018
Time: 7.15 am Registration, 7.30–8.00 am Breakfast, 8.00–9.00 am Presentation
Venue: The Royal Society of Victoria, 8 La Trobe St, Melbourne
Speakers:
- Dr Charlie Day, CEO Office of Innovation and Science
- David Mast, Enterprise Sales at IBM Watson Health, GCG and Japan
- Prof Linda Kristjanson AO Vice-Chancellor of Swinburne
- Mounir Kiwan, Corporate Affairs Manager – Bosch Australia
- Dr Kathy Nielsen, Director of Commercialisation for Life Sciences, Monash University
Price: $55 (inc GST)
All proceeds of this event go to support Innovation Week 2018
This event is hosted by BioMelbourne Network and the Australian Science & Innovation Forum.
Dr Charlie Day is the inaugural permanent CEO of the Office of Innovation and Science Australia (OISA) which supports the ISA board.
Charlie has a strong track record in innovation, science, research and commercialisation; and in facilitating the development of Australian start-ups and new technology-based ventures.
Charlie was most recently the Project Director, The Carlton Connect Initiative at The University of Melbourne. Prior to this, he was the leader of Melbourne Ventures, the technology commercialisation company of the University of Melbourne, from its foundation in 2004 until 2010. He also has a longstanding interest in the creation of new technology-based ventures, having previously been a member of the Investment Committee of the Venture Capital fund Uniseed, and more recently a co-founder of the Melbourne Accelerator Program.
Earlier in his career, Charlie was a consultant with the Boston Consulting Group, and before that, a consultant with Hagen & Co, an innovative startup consulting company focused on manufacturing process improvement.
Charlie currently serves on the board of the Murdoch Childrens’ Research Institute and is a member of their Translation and Commercialisation Committee.
Charlie has a degree in classics and an honours degree in chemical engineering from the University of Melbourne, along with a doctorate in jet engine design from Oxford University, where he studied as a Rhodes Scholar. He has also trained in corporate finance at INSEAD, and is a graduate of the Company Directors’ Course run by the Australian Institute of Company Directors.
David Mast leads Business Development for the Watson Health business unit in China and Japan.
Supporting IBM's aim of transforming healthcare thru the use of Augmented Intelligence, his focus is cancer treatments using IBM's Watson for Oncology, Genomics and Clinical Trials Matching solutions. Medical Imaging, Value-based care, Payer|Provider systems and Government Health and Human Services are also in scope.
Until recently David led the sales effort for IBM's Asia Pacific Cloud Platform and was responsible for design led outcomes mainly alongside the "Coder" generation.
David has worked for 30 years in the IT Industry, 22 of those in various IBM management roles: he also spent 10 years in the music and advertising Industries.
He holds a Master of Business Administration from Monash University.
Professor Kristjanson is Vice-Chancellor of Swinburne University. She also Chairs the Board of the Victorian Comprehensive Cancer Centre. Professor Kristjanson is a Fellow of the Australian Institute of Company Directors and Australian Academy of Technology & Engineering. Her academic career spans three decades across Australia, Canada and the United States. Before her current role, Professor Kristjanson was Deputy Vice-Chancellor Research and Development at Curtin University (2006-2011). She has an extensive research career in palliative care and was the inaugural Chair of Palliative Care, funded by the Cancer Council of Western Australia (2001-2006).
Professor Kristjanson was a member of the Board of the National Health & Medical Research Council (2003-2006). She has served as Non-Executive Director of a number of boards including the Cooperative Research Centre for Spatial Information and the Australian Biosecurity CRC for Emerging Infectious Diseases. In 2002 Professor Kristjanson was named the Australian Telstra Business Woman of the Year in recognition of her entrepreneurial work in health, science and innovation. She was Chair of AuScope Ltd (2008-2017) and served as Non-Executive Director of AARNET, the Australian Synchrotron Holding Company Ltd., and the International Centre for Radioastronomy Research.
In 2007 she was awarded the Royal College of Physicians and Surgeons of Canada Balfour Mount Professorship in Palliative Medicine. In 2012 she received a lifetime achievement award from the Bethlehem Griffith Research Foundation.
In 2017, Professor Kristjanson was made an Officer of the Order of Australia, in honour of distinguished service to tertiary education through leadership and governance roles, strategic and innovative university reforms, contributions to cancer research and palliative care, and to women.
Mounir is responsible for Corporate Affairs at Robert Bosch (Australia) with a portfolio across corporate communications, government affairs, public relations and special projects.
Mounir was previously General Manager at the Federation of Automotive Products Manufacturers (FAPM), the lead industry body in automotive manufacturing and Business Development Manager for Better Place, a global electric vehicle start-up that raised more than $850m in venture capital. He has also worked as a Ministerial Adviser for the Victorian Government.
Mounir is a Non-Executive Director of the Society of Automotive Engineers Australasia (SAE-A) and The Co-op/Australian Geographic. He was previously Company Secretary of EV Engineering, a consortium of companies that developed Australia’s only pure electric car.
Currently Director Commercialisation (Life Sciences) at Monash University, Kathy has responsibility for an extensive portfolio of assets (therapeutic, diagnostic, biomaterials), and has secured numerous valuable deals with pharmaceutical companies and VC investors.
Kathy has >25 years in the biomedical/pharma sector having a strong track record in deal-making, finance and IP, bolstered by a solid background in drug development across a range of therapeutic areas. Previously, as a senior executive Queensland Investment Corporation, Kathy managed numerous investments across four venture capital funds (2 in the USA) leading to healthy investment returns.
Kathy’s overarching aim is to help in the development of better drugs and make them available to the people who need them. In 2016, she was hugely honoured to be invited to provide expert advice for the Senate Inquiry into the Availability of New, Innovative Cancer Drugs in Australia and by the Pharmaceutical Benefits Advisory Committee for the reimbursement of olaparib, a first-in-class parp inhibitor.
She has held 17 board positions and is currently Director of HealthCare Pharmaceuticals, Kinoxis, WolfBio and Cincera P/L.
